MarketsSingle-source
2.0
Kymera Therapeutics files 8-K regarding executive and director changes
SEC EDGAR 8-K FilingsLO·US·about 4 hours ago
MarketsSingle-sourceLow
2.0
Sarepta Therapeutics files 8-K regarding executive and director changes
Sarepta Therapeutics has filed an 8-K disclosing changes to its board of directors or executive leadership, alongside compensatory arrangements. The filing indicates a shift in corporate governance or management structure, though specific details on the individuals involved remain to be parsed from the full exhibit.
Score Breakdown
Mosaic Score2.0
Confidence0.9
Significance0.1
Source credibility0.1
Intelligence Tags
Locations
Cambridge
Entities
country
Related signals
8 foundMarketsSingle-source
2.0
SPX Technologies, Inc. reports executive or director departure via 8-K filing
SEC EDGAR 8-K FilingsLO·US·about 14 hours ago
MarketsNotableSingle-source
5.1
Lattice Semiconductor Corp Files 8-K Reporting Executive Changes and Financial Obligations
SEC EDGAR 8-K FilingsLO·US·about 4 hours ago
MarketsSingle-source
2.0
HPS Net Lease Income REIT files 8-K regarding material agreements and leadership changes
SEC EDGAR 8-K FilingsLO·US·about 5 hours ago
MarketsSingle-source
2.0
Lyft Inc. reports executive or director departure via SEC 8-K filing
SEC EDGAR 8-K FilingsLO·US·about 4 hours ago
MarketsSingle-source
2.0
Customers Bancorp, Inc. reports executive or director departure via 8-K filing
SEC EDGAR 8-K FilingsLO·US·about 3 hours ago
MarketsSingle-source
2.0
XPO, Inc. files 8-K regarding executive management changes and compensatory arrangements
SEC EDGAR 8-K FilingsLO·US·about 13 hours ago
HealthNotableConfirmed
10.0
AstraZeneca targets $80 billion annual revenue by 2030 driven by oncology portfolio
Börsen-Zeitung·GB·about 16 hours ago